Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yoshino Ishioka"'
Autor:
Naoki Kohira, Meredith A. Hackel, Yoshino Ishioka, Miho Kuroiwa, Daniel F. Sahm, Takafumi Sato, Hideki Maki, Yoshinori Yamano
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 22, Iss , Pp 738-741 (2020)
Objective: To investigate possible mechanistic factors to explain cefiderocol (CFDC) non-susceptibility, we characterized 38 clinical isolates with a CFDC minimum inhibitory concentration (MIC) of >4 μg/mL from a multi-national surveillance study. M
Externí odkaz:
https://doaj.org/article/72046124350d4e22babc3f2d708785a5
Autor:
Christian M. Gill, Kamilia Abdelraouf, Merime Oota, Rio Nakamura, Miho Kuroiwa, Yoshino Ishioka, Miki Takemura, Yoshinori Yamano, David P. Nicolau
Publikováno v:
JAC-Antimicrobial Resistance. 4
Objectives This study evaluated the sustained kill and potential for resistance development of Acinetobacter baumannii exposed to human-simulated exposure of cefiderocol over 72 h in in vitro and in vivo infection models. Methods Seven A. baumannii i
Autor:
Christian M, Gill, Kamilia, Abdelraouf, Merime, Oota, Rio, Nakamura, Miho, Kuroiwa, Yoshino, Ishioka, Miki, Takemura, Yoshinori, Yamano, David P, Nicolau
Publikováno v:
JAC-antimicrobial resistance. 4(3)
This study evaluated the sustained kill and potential for resistance development ofSevenIn theThe discrepancy in the sustained efficacy and resistance emergence between
Autor:
Gill, Christian M., Abdelraouf, Kamilia, Merime Oota, Rio Nakamura, Miho Kuroiwa, Yoshino Ishioka, Miki Takemura, Yoshinori Yamano, Nicolau, David P.
Publikováno v:
JAC-Antimicrobial Resistance; Jun2022, Vol. 4 Issue 3, p1-8, 8p
Autor:
Hideki Maki, Takafumi Sato, Miho Kuroiwa, Naoki Kohira, Meredith Hackel, Daniel F. Sahm, Yoshino Ishioka, Yoshinori Yamano
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 22, Iss, Pp 738-741 (2020)
Objective To investigate possible mechanistic factors to explain cefiderocol (CFDC) non-susceptibility, we characterized 38 clinical isolates with a CFDC minimum inhibitory concentration (MIC) of >4 μg/mL from a multi-national surveillance study. Me
Autor:
Yoshino Ishioka, Yumi Tona, Wataru Nogami, Ryu Kanzaki, Hajime Yamada, Soichiro Funaki, Mitsunobu Matsumoto, Hidekazu Tanaka, Taisei Nomura, Yasushi Shintani, Kenji Kuwabara, Shigeki Adachi, Meinoshin Okumura, Soichi Tofukuji, Yoko Yamamoto
Publikováno v:
Cancer Research. 79:372-372
Despite the success of immune checkpoint therapy, most non-small cell lung cancer (NSCLC) patients still receive conventional chemotherapy. Overcoming chemotherapy resistance by identifying specific targets should improve cancer treatment and patient
Autor:
Takafumi Sato, Takeshi Ota, Ikue Sakikawa, Ishii Ryuta, Masakatsu Tsuji, Yoshinori Yamano, Naoko Kurihara, Toru Nishikawa, Akinobu Ito, Miho Kuroiwa, Masatomo Rokushima, Yoshino Ishioka
Publikováno v:
Open Forum Infectious Diseases
Background Cefiderocol (S-649266, CFDC) is a novel siderophore cephalosporin with activity against a wide variety of Gram-negative bacteria including carbapenem-resistant strains. We previously reported that CFDC is efficiently transported into Pseud